SNAKES Trial: Jelly Snakes to Prevent PONV in Kids After ENT Surgery
Launched by PROF. THOMAS ENGELHARDT · Mar 14, 2019
Trial Information
Current as of June 15, 2025
Unknown status
Keywords
ClinConnect Summary
Primary Hypothesis Chewing large jelly snakes will significantly reduce the development of postoperative vomiting in paediatric patients in the first 6 hours after volatile anaesthetic-based general anaesthesia for tonsillectomies +/- adenoidectomies.
Secondary Hypotheses:
1. Jelly snakes will reduce the incidence of nausea in the first 6 hours after tonsillectomy +/- adenoidectomy surgery
2. Jelly snakes will reduce rescue treatments for PONV in the first 6 hours
3. Jelly snakes will reduce the incidence of PONV in the first 24 hours or up until discharge in case of tonsillectomies (what...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Volatile anaesthetic-based general anaesthesia
- • Written informed parental consent
- • Elective tonsillectomy +/- adenoidectomy (+/- myringotomy, EUA ear, grommets or cautery of inferior turbinates')
- Exclusion Criteria:
- • Plan to use muscle relaxant
- • Plan to use topical lignocaine on the vocal cords intraoperatively
- • Contraindication to chewy jelly snakes or any of their components e.g. known allergy to any of the ingredients of the chewy jelly snakes or impaired pharyngeal/oesophageal function (e.g. bulbar palsy, achalasia), children with diabetes and vegetarian children
- • Contraindication to any protocolised anti-emetic drug (prophylaxis, intervention or rescue)
- • Parents/guardians or children who, in the opinion of the investigator, may be unable to understand or give informed consent will be excluded from the study.
About Prof. Thomas Engelhardt
Professor Thomas Engelhardt is a distinguished clinical trial sponsor renowned for his contributions to biomedical research and innovative therapeutic development. With a robust academic background and extensive experience in clinical trial design and execution, he leads initiatives that prioritize patient safety and efficacy outcomes. His collaborative approach fosters partnerships with leading research institutions, ensuring the integration of cutting-edge methodologies and adherence to regulatory standards. Committed to advancing medical knowledge, Professor Engelhardt's trials encompass a range of therapeutic areas, aiming to translate scientific discoveries into tangible health benefits for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials